Exclusion Criteria:~* Pregnant or breastfeeding~* Inability to tolerate MRI procedures or contraindication to
MRI~* Contraindication to PET imaging~* Residence in a skilled nursing facility~* Any serious medical condition
or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe
participation in and completion of the study, or bias the assessment of the clinical or mental status of the
participant to a significant degree~* Any evidence of a condition other than AD that may affect cognition~*
Substance abuse within the past 2 years~* Use of any experimental therapy within 90 days or 5 half-lives prior
to screening, whichever is greater, or any passive immunotherapy against tau~* Use of any passive immunotherapy
(immunoglobulin) against AÎ², unless the last dose was at least 1 year prior to screening or any active
immunotherapy (vaccine) that is under evaluation to prevent or postpone cognitive decline~* Any other biologic
therapy or previous treatment with medications specifically intended to treat Parkinsonian symptoms or any
other non-AD neurodegenerative disorder within 1 year of screening~* Systemic immunosuppressive therapy within
12 months of screening through the entire study period~* Typical antipsychotic or neuroleptic medication within
6 months of screening~* Daily treatment with any of the following classes of medication (except for
intermittent short-term use): opiates or opioids, benzodiazepines, barbiturates, hypnotics, or any medication
with clinically significant centrally-acting antihistamine or anticholinergic activity~* Stimulant medications,
unless the dose has been stable within the 6 months prior to screening and is expected to be stable throughout
the study
